Maria R. Baer

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes et al. · New England Journal of Medicine · 2019 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +15

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal Shah, Armin Ghobadi, Olalekan O. Oluwole et al. · The Lancet · 2021 · 769 citations · Full text

Medicine, Hematology, Oncology +9

<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

Guido Marcucci, Kati Maharry, Yue-Zhong Wu et al. · Journal of Clinical Oncology · 2010 · 764 citations · Full text

Medicine, Hematology, Oncology +17

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes et al. · The Lancet Oncology · 2017 · 488 citations · Full text

Medicine, Oncology, Pharmacology +10

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet et al. · Journal of Clinical Oncology · 2012 · 406 citations · Full text

Life Sciences, Hematology, Oncology +15